Opinion|Videos|December 6, 2024
Final Clinical Perspectives: EV+P is the New Standard of Care in Frontline Treatment of UC
Author(s)Thomas Powles MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MD, discusses how according to the ESMO guidelines, enfortumab vedotin plus pembrolizumab (EV+P) has become the new standard of first-line therapy in advanced urothelial carcinoma, and if there are patients who are ineligible for EV+P, alternatives are available such as nivolumab plus cisplatin/gemcitabine or platinum-based chemotherapy followed by maintenance avelumab.
Advertisement
Episodes in this series
Advertisement
Related to this article
Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
Camrelizumab Plus Nab-Paclitaxel Yields Efficacy in Previously Treated Advanced Urothelial Carcinoma
Later-line camrelizumab plus nab-paclitaxel produced durable responses in platinum-treated advanced urothelial carcinoma.
First-line tislelizumab plus gemcitabine produced durable responses in platinum-ineligible locally advanced or metastatic urothelial carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
The OncFive: Top Oncology Articles for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5